Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ADAP
- CUSIP: N/A
- Web: www.adaptimmune.com
Average Prices:- 52 Week Range: $3.76 - $9.29
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.01
- P/E Growth: 0.00
Profitability:- Net Margins: -438.00%
- Return on Equity: -38.73%
- Return on Assets: -30.14%
Debt:- Current Ratio: 7.86%
- Quick Ratio: 7.86%
Misc:- Average Volume: 520,957 shs.
- Beta: 1.28
Frequently Asked Questions for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
What is Adaptimmune Therapeutics PLC's stock symbol?
Adaptimmune Therapeutics PLC trades on the NASDAQ under the ticker symbol "ADAP."
How were Adaptimmune Therapeutics PLC's earnings last quarter?
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.24) EPS for the quarter, meeting analysts' consensus estimates of ($0.24). The business had revenue of $3.52 million for the quarter, compared to analysts' expectations of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. View Adaptimmune Therapeutics PLC's Earnings History.
When will Adaptimmune Therapeutics PLC make its next earnings announcement?
Where is Adaptimmune Therapeutics PLC's stock going? Where will Adaptimmune Therapeutics PLC's stock price be in 2017?
5 equities research analysts have issued 12 month price targets for Adaptimmune Therapeutics PLC's shares. Their forecasts range from $15.00 to $16.00. On average, they expect Adaptimmune Therapeutics PLC's stock price to reach $15.50 in the next twelve months. View Analyst Ratings for Adaptimmune Therapeutics PLC.
What are analysts saying about Adaptimmune Therapeutics PLC stock?
Here are some recent quotes from research analysts about Adaptimmune Therapeutics PLC stock:
- 1. According to Zacks Investment Research, "Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. " (7/17/2017)
- 2. Cowen and Company analysts commented, "Adaptimmune reported updated data from its Phase II trial of NY-ESO SPEAR T cells." (6/6/2017)
Who are some of Adaptimmune Therapeutics PLC's key competitors?
Some companies that are related to Adaptimmune Therapeutics PLC include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Spark Therapeutics (ONCE), Sarepta Therapeutics (SRPT) and AveXis (AVXS).
Who are Adaptimmune Therapeutics PLC's key executives?
Adaptimmune Therapeutics PLC's management team includes the folowing people:
- James Julian Noble, Chief Executive Officer, Director
- Adrian Rawcliffe, Chief Financial Officer
- William C. Bertrand Jr. Esq., Chief Operating Officer
- Gwendolyn Binder-Scholl Ph.D., Chief Technology Officer
- William Roberts, Vice President of Investor Relations
- Rafael Amado M.D., Chief Medical Officer
- Helen Katrina Tayton-Martin Ph.D., Chief Business Officer
- David M. Mott, Non-Executive Chairman of the Board
- Lawrence M. Alleva, Non-Executive Independent Director
- Ali Behbahani M.D., Non-Executive Independent Director
When did Adaptimmune Therapeutics PLC IPO?
(ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.
Who owns Adaptimmune Therapeutics PLC stock?
Adaptimmune Therapeutics PLC's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
MATRIX CAPITAL MANAGEMENT COMPANY, LP
(12.90%), NEA Management Company LLC (12.86%), Matrix Capital Management Company LP (0.00%), Capital World Investors (0.00%), FMR LLC (5.63%) and Tekla Capital Management LLC (0.00%). Company insiders that own Adaptimmune Therapeutics PLC stock include Charles Elliott Sigal, Enterprise Associates 14 New and Orbimed Advisors Llc. View Institutional Ownership Trends for Adaptimmune Therapeutics PLC.
Who sold Adaptimmune Therapeutics PLC stock? Who is selling Adaptimmune Therapeutics PLC stock?
Who bought Adaptimmune Therapeutics PLC stock? Who is buying Adaptimmune Therapeutics PLC stock?
Adaptimmune Therapeutics PLC's stock was bought by a variety of institutional investors in the last quarter, including Matrix Capital Management Company LP, Baillie Gifford & Co., Balyasny Asset Management LLC, Essex Investment Management Co. LLC, GSA Capital Partners LLP, OxFORD Asset Management LLP, Virtu KCG Holdings LLC and Alps Advisors Inc.. Company insiders that have bought Adaptimmune Therapeutics PLC stock in the last two years include Charles Elliott Sigal, Enterprise Associates 14 New and Orbimed Advisors Llc. View Insider Buying and Selling for Adaptimmune Therapeutics PLC.
How do I buy Adaptimmune Therapeutics PLC stock?
Shares of Adaptimmune Therapeutics PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adaptimmune Therapeutics PLC's stock price today?
One share of Adaptimmune Therapeutics PLC stock can currently be purchased for approximately $7.93.
MarketBeat Community Rating for Adaptimmune Therapeutics PLC (NASDAQ ADAP)MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Adaptimmune Therapeutics PLC (NASDAQ:ADAP) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.40) |
| Consensus Price Target: | $15.50 (95.46% upside) |
Analysts' Ratings History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/8/2017 | Leerink Swann | Reiterated Rating | Outperform | $15.00 | Low |  |
| 6/6/2017 | Cowen and Company | Reiterated Rating | Buy | | Low | |
| 3/17/2017 | Wells Fargo & Company | Initiated Coverage | Market Perform -> Market Perform | | Low | |
| 10/24/2016 | Bank of America Corporation | Downgrade | Neutral -> Underperform | | N/A | |
| 9/30/2016 | Raymond James Financial, Inc. | Initiated Coverage | Outperform | $16.00 | N/A | |
| 2/27/2016 | Deutsche Bank AG | Initiated Coverage | Buy | | N/A | |
| 2/25/2016 | Citigroup Inc. | Initiated Coverage | Buy | $15.00 | N/A | |
| 12/22/2015 | SunTrust Banks, Inc. | Initiated Coverage | Buy | $16.00 | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)Earnings History by Quarter for Adaptimmune Therapeutics PLC (NASDAQ ADAP)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/9/2017 | | | | | | | | |
| 8/3/2017 | 6/30/2017 | ($0.24) | ($0.24) | $5.43 million | $3.52 million | View | N/A | |
| 5/10/2017 | 3/31/2017 | ($0.24) | ($0.30) | $5.07 million | $2.86 million | View | N/A | |
| 3/13/2017 | 12/31/2016 | ($0.27) | ($0.22) | $3.98 million | $8.54 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)2017 EPS Consensus Estimate: ($1.04)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.27) | ($0.24) | ($0.26) |
| Q2 2017 | 2 | ($0.26) | ($0.24) | ($0.25) |
| Q3 2017 | 2 | ($0.27) | ($0.25) | ($0.26) |
| Q4 2017 | 2 | ($0.29) | ($0.25) | ($0.27) |
(Data provided by Zacks Investment Research)
Dividend History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)Insider Ownership Percentage: 24.45%
Institutional Ownership Percentage: 68.01%
Insider Trades by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/27/2017 | Enterprise Associates 14 New | Major Shareholder | Buy | 12,870,000 | $0.70 | $9,009,000.00 | |
| 3/27/2017 | Orbimed Advisors Llc | Director | Buy | 1,190,476 | $4.20 | $4,999,999.20 | |
| 5/24/2016 | Orbimed Advisors Llc | Director | Buy | 1,712,400 | $10.42 | $17,843,208.00 | |
| 5/19/2016 | Charles Elliott Sigal | Director | Buy | 15,000 | $1.56 | $23,400.00 | |
| 5/18/2016 | Charles Elliott Sigal | Director | Buy | 45,000 | $1.53 | $68,850.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Latest Headlines for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
| Source: |
|
| Date | Headline |
|---|
 | Surging Earnings Estimates Signal Good News for Adaptimmune ... - Nasdaq
www.nasdaq.com - September 23 at 3:37 PM |
 | Surging Earnings Estimates Signal Good News for Adaptimmune Therapeutics (ADAP)
finance.yahoo.com - September 23 at 9:36 AM |
| James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
finance.yahoo.com - September 23 at 9:36 AM |
 | Critical Contrast: Ritter Pharmaceuticals (RTTR) vs. Adaptimmune Therapeutics PLC (ADAP)
www.americanbankingnews.com - September 17 at 2:50 PM |
| European ADRs Fractionally Higher as Manufacturers Advance
www.nasdaq.com - September 15 at 3:51 PM |
| Zacks.com featured highlights: Adaptimmune Therapeutics, Barnes Group, Mobile TeleSystems, JA Solar Holdings and Newtek Business Services
finance.yahoo.com - September 13 at 3:57 PM |
| Adaptimmune Therapeutics PLC (ADAP) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - September 12 at 4:48 PM |
 | BRIEF-Matrix Capital reports 12.9 pct passive stake in Adaptimmune Therapeutics
www.reuters.com - September 12 at 2:06 AM |
| Analysts Anticipate Adaptimmune Therapeutics PLC (ADAP) Will Announce Quarterly Sales of $3.14 Million
www.americanbankingnews.com - September 10 at 3:26 AM |
| Adaptimmune Therapeutics PLC (ADAP) Expected to Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - September 9 at 12:20 AM |
| Adaptimmune Therapeutics PLC's (ADAP) Outperform Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - September 8 at 9:52 PM |
| BRIEF-GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO
www.reuters.com - September 7 at 8:27 PM |
 | GSK Exercising Option Further Validates Adaptimmune (ADAP) TCR Platform - Leerink
www.streetinsider.com - September 7 at 8:27 PM |
| Adaptimmune Therapeutics Plc :ADAP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017
finance.yahoo.com - September 6 at 3:25 PM |
 | Mersana Appoints Lawrence M. Alleva to Board of Directors Nasdaq ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 1:58 AM |
| Strength Seen in Adaptimmune Therapeutics (ADAP): Stock Soars 15.2% - Nasdaq
www.nasdaq.com - August 31 at 3:23 PM |
| Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker - GlobeNewswire (press release)
globenewswire.com - August 30 at 3:15 PM |
| Strength Seen in Adaptimmune Therapeutics (ADAP): Stock Soars 15.2%
finance.yahoo.com - August 29 at 3:45 PM |
 | More Immunotherapy Buyouts Likely After Kite Sale - TheStreet.com
www.thestreet.com - August 28 at 8:40 PM |
| Adaptimmune Therapeutics PLC (ADAP) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - August 26 at 12:56 AM |
| $3.14 Million in Sales Expected for Adaptimmune Therapeutics PLC (ADAP) This Quarter
www.americanbankingnews.com - August 23 at 11:06 AM |
| Adaptimmune Therapeutics PLC (ADAP) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 18 at 5:26 PM |
| $5.43 Million in Sales Expected for Adaptimmune Therapeutics PLC (NASDAQ:ADAP) This Quarter
www.americanbankingnews.com - August 5 at 9:32 AM |
| Adaptimmune Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 4 at 3:32 PM |
| Adaptimmune Therapeutics PLC (ADAP) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 3 at 4:50 PM |
| Adaptimmune Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 4:29 PM |
| Zacks: Brokerages Expect Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Will Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - August 3 at 7:26 AM |
| Adaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017
finance.yahoo.com - July 31 at 8:45 PM |
| Adaptimmune Therapeutics PLC (ADAP) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 24 at 2:16 PM |
| Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - July 21 at 12:44 AM |
| Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 17 at 9:40 PM |
| Adaptimmune Therapeutics PLC (ADAP) Expected to Announce Quarterly Sales of $5.43 Million
www.americanbankingnews.com - July 13 at 9:18 AM |
| Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - July 12 at 8:26 PM |
| Adaptimmune Therapeutics PLC (ADAP) Expected to Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - July 11 at 8:24 PM |
| Adaptimmune Therapeutics PLC (ADAP) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - July 8 at 9:32 PM |
| Adaptimmune Therapeutics PLC (ADAP) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - June 27 at 2:39 PM |
| Brokerages Anticipate Adaptimmune Therapeutics PLC (ADAP) Will Announce Quarterly Sales of $5.43 Million
www.americanbankingnews.com - June 17 at 7:58 AM |
| Analysts Expect Adaptimmune Therapeutics PLC (ADAP) Will Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - June 15 at 8:22 PM |
| European ADRs Move Higher in Wednesday Trading
www.nasdaq.com - June 14 at 8:21 PM |
 | BioLife Solutions Executes Supply Agreement with Adaptimmune for ... - PR Newswire (press release)
www.prnewswire.com - June 14 at 3:20 PM |
| BRIEF-Biolife Solutions executes supply agreement with Adaptimmune for Cryostor
www.reuters.com - June 14 at 8:44 AM |
 | BioLife Solutions Executes Supply Agreement with Adaptimmune for CryoStor® Use in SPEAR T-Cell Platform
www.bizjournals.com - June 14 at 8:44 AM |
| Ewing Sarcoma Pipeline Analysis by Stage of Development, Drug Target and Molecule Type New Report Available at RnRMarketResearch.com
www.bizjournals.com - June 13 at 3:20 PM |
 | Adaptimmune Therapeutics (ADAP) Presents At American Society Of Clinical Oncology 2017 Annual Meeting - Slideshow
seekingalpha.com - June 8 at 8:25 PM |
| Adaptimmune Therapeutics (ADAP) Delivers Data from NY-ESO Study in Synovial Sarcoma & Four Trials at ASCO ... - StreetInsider.com
www.streetinsider.com - June 6 at 3:32 PM |
| Adaptimmune Therapeutics PLC - (ADAP) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - June 6 at 1:40 PM |
| Adaptimmune Therapeutics (ADAP) Delivers Data from NY-ESO Study in Synovial Sarcoma & Four Trials at ASCO Meetings
www.streetinsider.com - June 5 at 1:28 PM |
| BRIEF-Adaptimmune announces data from NY-ESO study in Synovial Sarcoma at ASCO annual meeting
www.reuters.com - June 5 at 1:28 PM |
| Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 5 at 1:28 PM |
| Adaptimmune Therapeutics Plc :ADAP-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 3:52 PM |
Adaptimmune Therapeutics PLC (ADAP) Chart for Sunday, September, 24, 2017
